10 Drugs Approved for Primary Care From the First Half of 2025

The first half of 2025 brought a wave of new FDA drug approvals, several of which have direct relevance for primary care. In the slideshow above, we highlight 10 new therapies from the first and second quarter that may soon find a place in your prescribing routine. Click through the slides above for details on the first new oral antibiotic for uncomplicated urinary tract infections in 30 years, a vaccine that provides coverage against 5 major serogroups of Neisseria meningitidis that affect young people, the first dihydroergotamine nasal powder product to be approved for the acute treatment of migraine in adults, the first targeted therapy approved for chronic spontaneous urticaria (CSU) in over 10 years, and 6 more.